文献速递胸部肿瘤头颈与中枢神经肿瘤

劳拉替尼治疗晚期间变性淋巴瘤激酶阳性非小细胞肺癌:IFCT-1803 LORLATU队列研究结果

Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.
PubMed 文献 · Eur J Cancer · 2022-03-09

该研究纳入2015年10月至2019年6月法国扩展准入计划中连续接受劳拉替尼治疗的208例晚期ALK阳性非小细胞肺癌患者,评估真实世界治疗序列及劳拉替尼疗效与安全性。中位无进展生存期为9.9个月(95%CI 6-12.3个月),总缓解率49%,疾病控制率86%,中枢神经系统客观缓解率56%。

要点

  • 劳拉替尼中位无进展生存期9.9个月(95%CI 6-12.3个月),中位总生存期32.9个月(95%CI 18.7个月至未达到)。
  • 总缓解率49%,疾病控制率86%,中枢神经系统客观缓解率56%。
  • 28例(14%)因毒性停止治疗,安全性特征与既往发表数据一致。

核心结论

  • 真实世界证据表明,劳拉替尼在经重度治疗的ALK阳性非小细胞肺癌患者中提供显著临床获益和高颅内抗肿瘤活性。

研究设计与样本

  • 纳入2015年10月至2019年6月法国扩展准入计划中连续接受劳拉替尼治疗的晚期ALK阳性非小细胞肺癌患者,共208例。
  • 数据由法国胸科肿瘤协作组独立研究人员从病历中收集和审核。
  • 主要终点为无进展生存期。

主要发现

  • 208例患者中,女性117例(56%),从不吸烟142例(69%),诊断时为IV期180例(87%),腺癌94%,中位年龄60.9岁。
  • 劳拉替尼启动时,160例(77%)有脑转移,125例(72%)体力状况评分为0/1。
  • 劳拉替尼作为二线/三线/四线/五线及以上治疗的比例分别为4%/17%/30%/49%。
  • 162例(78%)既往接受过化疗,194例(93%)接受过第一代ALK酪氨酸激酶抑制剂,195例(94%)接受过第二代ALK酪氨酸激酶抑制剂。
  • 自劳拉替尼启动的中位随访时间为23.3个月;中位无进展生存期9.9个月(95%CI 6-12.3个月),自劳拉替尼启动的中位总生存期32.9个月(95%CI 18.7个月至未达到),自晚期非小细胞肺癌诊断的中位总生存期97.3个月(95%CI 75.7-152.8个月)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) represents a rare subset of lung cancer, with specific presentation, and multiple treatment options, including selective tyrosine kinase inhibitors (TKIs). Real-world evidence is insufficient regarding the actual real-life treatment sequences in the late line setting, and available clinical trials may not reflect real-world situation. Here, we took advantage of the French Expanded Access Program (EAP) of lorlatinib, a third-generation TKI targeting ALK and ROS1, to assess treatment sequencing, and lorlatinib efficacy and safety, in patients with ALK+ NSCLC. METHODS: All consecutive patients with advanced ALK+ NSCLC treated between October 2015 and June 2019 with lorlatinib as part of EAP were included. Data were collected and reviewed from medical records by independent research staff of the French Thoracic Cancer Intergroup. The primary endpoint was progression-free survival (PFS). RESULTS: Of the 208 patients included, 117 (56%) were female, 142 (69%) were never smokers, and 180 (87%) had stage IV NSCLC at diagnosis. The most frequent histology was adenocarcinoma (94%), and the median age was 60.9 years. At the time of lorlatinib initiation, 160 (77%) patients had brain metastases, and 125 (72%) were performance status 0/1. Lorlatinib was delivered as 2nd/3rd/4th/5th+ line in 4%/17%/30%/49% of patients. A total of 162 (78%) patients had previously been treated with chemotherapy, 194 (93%) with a first-generation ALK-TKI, 195 (94%) with a second-generation ALK-TKI. The median follow-up from lorlatinib initiation was 23.3 months. The median PFS, median overall survival (OS) from lorlatinib initiation and median OS from advanced NSCLC diagnosis were 9.9 months (95% confidence interval [CI] 6-12.3 months), 32.9 months (95% CI 18.7 months to not reached) and 97.3 months (95% CI 75.7-152.8 months), respectively. The median duration of treatment with lorlatinib was 11.8 months (95% CI 8.5-18.8 months). Overall response and disease control rate were 49% and 86%, respectively. Central nervous system objective response rate was 56%. Treatment was stopped due to toxicity in 28 patients (14%). The safety profile of lorlatinib was consistent with previously published data. CONCLUSIONS: Real-world evidence indicates that lorlatinib offers a significant clinical benefit and high intracerebral antitumour activity in heavily pretreated patients with ALK+ NSCLC. GOV IDENTIFIER: NCT03727477.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Baldacci S, Besse B, Avrillon V, et al. Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort. Eur J Cancer. 2022. PMID: 35278825. doi:10.1016/j.ejca.2022.01.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。